Share Twitter LinkedIn Facebook Email Sattva Neelapu, M.D. Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Discusses Next Step In ZUMA Studies At The 60th ASH Annual Meeting on Dec 1, 2018.
FDA Approves Adcetris / brentuximab vedotin + lenalidomide & rituximab in relapsed or refractory LBCL: Could This Change Standard Care? Lymphoma 2 Mins Read
2024 Update on Lymphoma Treatment: Navigating the Latest Advances – Elizabeth Brem, MD [38 Slides] Hodgkin Lymphoma 4 Mins Read
FDA Grants Accelerated Approval to Zanubrutinib (Brukinsa) for Relapsed or Refractory Follicular Lymphoma Lymphoma 2 Mins Read